The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer. (11th December 2019)

• Record Type: Journal Article
• Authors: Salati, Massimiliano; Filippi, Roberto; Vivaldi, Caterina; Caputo, Francesco; Leone, Francesco; Salani, Francesca; Cerma, Krisida; Aglietta, Massimo; Fornaro, Lorenzo; Sperti, Elisa; Di Maio, Massimo; Ortega, Cinzia; Fenocchio, Elisabetta; Lombardi, Pasquale; Cagnazzo, Celeste; Depetris, Ilaria; Gelsomino, Fabio; Spallanzani, Andrea; Santini, Daniele; Silvestris, Nicola; Aprile, Giuseppe; Roviello, Giandomenico; Scartozzi, Mario; Cascinu, Stefano; Casadei‐Gardini, Andrea
• Is Part Of: Liver international. Volume 40:Number 3(2020)
• Page Start: 704
• Page End: 711
• Publication Date: 2019-12-11
• Subjects: biliary tract cancer -- chemotherapy -- cholangiocarcinoma -- gallbladder cancer -- prognosis -- prognostic nutritional index -- response prediction -- survival; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14314
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background: An accurate risk‐stratification is key to optimize the benefit‐to‐risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing the impact of the prognostic nutritional index (PNI) on survival and treatment response in advanced biliary cancer (ABC) receiving first‐line chemotherapy. Methods: Medical records of ABC treated with standard chemotherapy at the Modena Cancer Centre were retrospectively reviewed for variables deemed of potential interest, including the PNI. Univariate and multivariate analyses were performed to investigate the association between the covariates and overall survival (OS). Results: 114 ABC fulfilled the inclusion criteria and made up the training cohort. A PNI cut‐off value of 36.7 was established using the receiver operating characteristic (ROC) analysis. At both the univariate and the multivariate analysis, low PNI value (<36.7) was associated with shorter OS ( P = .0011), together with increased NLR ( P = .0046) and ECOG >1 ( P < .0001). The median OS was 5.4 vs 12.1 months in the low‐ vs high PNI‐group. Moreover, a PNI value >36.7 resulted in a higher disease control in patients treated with gemcitabine/platinum combination (61.4% vs 34.3%). These results were validated in an independent cohort of 253 ABC. Conclusions: We demonstrated and externally validated a prognostic role for the PNI in ABC treated with first‐line chemotherapy. Although the PNI turned out to be predictive in the subset of patients receiving platinum/gemcitabine combination, future prospective confirmation is needed.